Project Grant W81XWH2210875
Award Date
9/15/22
Completion Date
9/14/24
Dollars Obligated
$4M
Federal Agency
Medical Command
Awardee
Theradaptive Inc. (DN45N68LM8M6)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Frederick, MD 21703, USA
Similar Awards
The U.S. Department of the Army Medical Command awarded a $4,324,139 Project Grant to Young Biopharma, LLC, a minority-owned biotech company in Andover, MA. The grant, funded under the Military Medical Research and Development (CFDA 12.420) program, supports the development of a novel TRP modulator, YB-16, to treat osteoarthritis knee pain. The 3-year project, with a completion date of June 14, 2028, aims to explore innovative approaches to managing this condition that is highly relevant to...
The Department of the Army Medical Command, through its Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $1,999,583 project grant to IRR Inc. located in Santa Barbara, CA. The funding supports an early-stage proof-of-concept study of a fixed-dose combination therapy in a high-fidelity porcine model of severe polytrauma. The 2-year project, running from July 1, 2025 to June 30, 2027, aims to explore innovative approaches to disease prevention, diagnosis,...
The Department of the Army Medical Command awarded a $409,121 project grant to the Rochester Institute of Technology under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the development of a novel 3D scleroderma skin model to test therapeutic modulation of TRPC6 from July 2022 through July 2025. Through this research, the awardee aims to advance the development of medical solutions for the battlefield by investigating potential treatments for...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,000,000.00 in funding to Tekhona Inc., a for-profit S corporation, to develop intra-articular immunoregulatory microparticles for inducing systemic remission in rheumatoid arthritis. The 2-year research project, with an award date of September 15, 2023 and an ultimate completion date of September 14, 2025, aims to transform healthcare for Service...
IHP Therapeutics Inc. was awarded a $217,928 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from March 2022 through September 2023 to develop a novel glycan therapeutic to treat Acute Respiratory Distress Syndrome. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions. This award...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $466,970.00 to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to conduct research toward ultra-long-term intra-articular delivery of disease-modifying biologics to reduce the progression of post-traumatic osteoarthritis. The award period is from February 15, 2025 to February 14, 2027....
The Department of the Army Medical Command has awarded a $5,468,175 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of Utah to develop a sustained-release drug delivery device to manage biofilm implant-related infections. The project, with a performance period from May 1, 2024 to April 30, 2028, will involve the University of Utah collaborating with Purgo Scientific LLC as a sub-awardee to advance this innovative medical technology. The...
The Department of the Army Medical Command awarded Treventis Corporation a $2,977,166 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the development of a small molecule anti-misfolding drug for frontotemporal degeneration from August 1, 2022 to July 31, 2025. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative solutions for battlefield...
The Department of the Army Medical Command awarded a $3,246,800 project grant to Duke University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2022 to June 30, 2026 to develop resorbable poly(ester urea) films for sustained delivery of meloxicam and bupivacaine to manage pain in critical combat casualty environments. Through basic, applied, and advanced biomedical research, the Military Medical Research and Development...
The Department of the Army Medical Command awarded Tufts University School of Medicine a $813,375 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to investigate metabolic modulation of collagens in the extracellular matrix to preserve GABAergic inhibition after traumatic brain injury. The three-year award beginning August 1, 2022 will support research into medical solutions for traumatic brain injuries sustained on the battlefield. A $813k sub-award...